Studi clinici su BPCO nello stato di Texas
25 studi su BPCO cercano partecipanti presso sedi nello stato di Texas.
Città nello stato di Texas
- Houston15 studi
- Dallas12 studi
- McKinney5 studi
- El Paso5 studi
- Cypress4 studi
- Mesquite4 studi
- Lewisville3 studi
- Denison3 studi
- The Woodlands3 studi
- Sugar Land3 studi
- San Antonio3 studi
- Grand Prairie3 studi
Testo ufficiale dello studio (inglese)
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- Solace Clinical Research- Site Number : 8400087, Austin
- IntraCare- Site Number : 8400034, Dallas
- Premier Pulmonary Critical Care and Sleep- Site Number : 8400111, Denison
- e altri 7
In reclutamentoFase 3
Età da 40 a 80 · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT07190222To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
- Horizon Clinical Research Group., Cypress
- Metroplex Pulmonary and Sleep Center, McKinney
- DM Clinical Research- Tomball, Tomball
In reclutamentoFase 2
Età da 40 a 85 · Tutti i sessi · Aggiornato il 30 set 2026 · NCT07684820A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
- Premier Pulmonary Critical Care and Sleep, Denison
- Baylor College of Medicine Medical Center, Houston
- Prime Clinical Research - Lewisville, Lewisville
In reclutamentoFase 2
Età da 40 a 75 · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07759245A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
- Copd01 50001, Boerne
In reclutamentoFase 2
Età da 40 a 80 · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07725939A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
- REX Clinical Trials - Beaumont- Site Number : 8400011, Beaumont
In reclutamentoFase 4
Età da 40 a 85 · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07053423Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- Wellness Clinical Research - Allen- Site Number : 8400085, Allen
- REX Clinical Trials - Beaumont- Site Number : 8400014, Beaumont
- Novel Research - Bellaire- Site Number : 8400116, Bellaire
- e altri 17
In reclutamentoFase 3
Età da 40 a 80 · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07190209An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
- University of Texas Southwestern, Dallas
In reclutamento
Età da 40 a 80 · Tutti i sessi · Aggiornato il 17 set 2026 · NCT06035120A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
- WB Contracted Clinical Research Site, McKinney
- WB Contracted Clinical Research Site, Waxahachie
In reclutamentoFase 2
Età da 40 a 80 · Tutti i sessi · Aggiornato il 15 set 2026 · NCT07646587A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Research Site, Boerne
- Research Site, Dallas
- Research Site, Denison
- e altri 5
In reclutamentoFase 2
Età 40 e oltre · Tutti i sessi · Aggiornato il 9 set 2026 · NCT07082738Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
- Baylor College of Medicine, Houston
In reclutamentoFase 2
Età 40 e oltre · Tutti i sessi · Aggiornato il 4 set 2026 · NCT07059091A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
- Research Site, Boerne
- Research Site, El Paso
- Research Site, Houston
- e altri 6
In reclutamentoFase 3
Età da 40 a 80 · Tutti i sessi · Aggiornato il 3 set 2026 · NCT06878261A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Research Site, Dallas
- Research Site, Forney
- Research Site, Fort Worth
- e altri 5
In reclutamentoFase 3
Età da 40 a 80 · Tutti i sessi · Aggiornato il 3 set 2026 · NCT06883305The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
- The Lung & Sleep Institute of North Texas, North Richland Hills
In reclutamentoStudio osservazionale
Età 40 e oltre · Tutti i sessi · Aggiornato il 1 set 2026 · NCT07612878A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- South Texas Medical Research Institute, Inc., DBA TTS Research, Boerne
- Ten20 Clinical Research, Carrollton
- Horizon Clinical Research Group, Cypress
- e altri 4
In reclutamentoFase 2/3
Età da 35 a 80 · Tutti i sessi · Aggiornato il 31 ago 2026 · NCT07363694A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Abilene
- Research Site, Brownsville
- Research Site, Dallas
- e altri 12
In reclutamentoFase 3
Età da 40 a 80 · Tutti i sessi · Aggiornato il 26 ago 2026 · NCT06283966A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
- GC2501 Study Site 109, Dallas
In reclutamentoFase 3
Età da 18 a 80 · Tutti i sessi · Aggiornato il 11 ago 2026 · NCT07555483STRIVE Post-Market Registry Study
- Baylor Scott & White Research Institute, Dallas
- University of Texas Southwestern, Dallas
- University of Texas Health Science Center at Houston, Houston
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 ago 2026 · NCT04302272eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Dallas
- GSK Investigational Site, DeSoto
- GSK Investigational Site, Greenville
- e altri 6
In reclutamentoFase 3
Età da 40 a 75 · Tutti i sessi · Aggiornato il 28 lug 2026 · NCT07177339Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
- Liver Center of Texas, Dallas
- Methodist Hospital, Richardson
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 lug 2026 · NCT05181826Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3
- Houston Methodist/Primary Critical Care, Houston
In reclutamento
Età da 40 a 84 · Tutti i sessi · Aggiornato il 24 apr 2026 · NCT06891755Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Austin
- GSK Investigational Site, Dallas
- GSK Investigational Site, El Paso
- e altri 5
In reclutamentoFase 3
Età da 40 a 80 · Tutti i sessi · Aggiornato il 9 apr 2026 · NCT06961214Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
- GSK Investigational Site, Corsicana
In reclutamentoFase 3
Età da 40 a 80 · Tutti i sessi · Aggiornato il 8 ott 2025 · NCT06959095Interprofessional Pharmacogenomics (IPGx) Registry and Repository
- Texas A&M Family Care, Bryan
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 12 set 2025 · NCT06726590Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- Horizon Clinical Research Group, Houston
- CHRISTUS Trinity Mother Frances Health System, Tyler
In reclutamentoStudio osservazionale
Età 50 e oltre · Tutti i sessi · Aggiornato il 5 ago 2025 · NCT06122077myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
- Respire Research Institute, Houston
In reclutamento
Età 30 e oltre · Tutti i sessi · Aggiornato il 6 feb 2025 · NCT05204888Fonte: ClinicalTrials.gov, dati recuperati il 2 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.